Ignite Creation Date:
2025-12-24 @ 10:56 PM
Ignite Modification Date:
2026-02-24 @ 12:25 AM
Study NCT ID:
NCT02650869
Status:
COMPLETED
Last Update Posted:
2016-01-08
First Post:
2015-12-31
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Role of Probiotics for Prevention of NEC in Preterm VLBW Infants
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D020345', 'term': 'Enterocolitis, Necrotizing'}], 'ancestors': [{'id': 'D004760', 'term': 'Enterocolitis'}, {'id': 'D005759', 'term': 'Gastroenteritis'}, {'id': 'D005767', 'term': 'Gastrointestinal Diseases'}, {'id': 'D004066', 'term': 'Digestive System Diseases'}, {'id': 'D007410', 'term': 'Intestinal Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D019936', 'term': 'Probiotics'}, {'id': 'D008895', 'term': 'Milk, Human'}], 'ancestors': [{'id': 'D019587', 'term': 'Dietary Supplements'}, {'id': 'D005502', 'term': 'Food'}, {'id': 'D000066888', 'term': 'Diet, Food, and Nutrition'}, {'id': 'D010829', 'term': 'Physiological Phenomena'}, {'id': 'D019602', 'term': 'Food and Beverages'}, {'id': 'D008892', 'term': 'Milk'}, {'id': 'D001628', 'term': 'Beverages'}, {'id': 'D003611', 'term': 'Dairy Products'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'DOUBLE', 'whoMasked': ['PARTICIPANT', 'INVESTIGATOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 60}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2012-07'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2016-01', 'completionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2016-01-07', 'studyFirstSubmitDate': '2015-12-31', 'studyFirstSubmitQcDate': '2016-01-07', 'lastUpdatePostDateStruct': {'date': '2016-01-08', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2016-01-08', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2015-12', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': "Necrotizing Enterocolitis: Occurrence of NEC (stage II and III) by Modified Bell's classification", 'timeFrame': '10 days', 'description': "The occurrence of NEC (stage II and III) by modified Bell's classification"}], 'secondaryOutcomes': [{'measure': 'Enteral feeding', 'timeFrame': '10 days', 'description': 'days to achieve full enteral feeding'}, {'measure': 'Hospital stay', 'timeFrame': '10 days', 'description': 'maximum days of hospital stay'}, {'measure': 'weight in Kg', 'timeFrame': '10 days', 'description': 'weight in kg'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Necrotizing Enterocolitis', 'probiotics', 'very low birth weight'], 'conditions': ['Necrotizing Enterocolitis']}, 'referencesModule': {'references': [{'pmid': '17336180', 'type': 'BACKGROUND', 'citation': 'Sharma R, Tepas JJ 3rd, Hudak ML, Mollitt DL, Wludyka PS, Teng RJ, Premachandra BR. Neonatal gut barrier and multiple organ failure: role of endotoxin and proinflammatory cytokines in sepsis and necrotizing enterocolitis. J Pediatr Surg. 2007 Mar;42(3):454-61. doi: 10.1016/j.jpedsurg.2006.10.038.'}, {'pmid': '16214770', 'type': 'BACKGROUND', 'citation': 'Forchielli ML, Walker WA. The effect of protective nutrients on mucosal defense in the immature intestine. Acta Paediatr Suppl. 2005 Oct;94(449):74-83. doi: 10.1111/j.1651-2227.2005.tb02159.x.'}, {'pmid': '10968793', 'type': 'BACKGROUND', 'citation': 'Neish AS, Gewirtz AT, Zeng H, Young AN, Hobert ME, Karmali V, Rao AS, Madara JL. Prokaryotic regulation of epithelial responses by inhibition of IkappaB-alpha ubiquitination. Science. 2000 Sep 1;289(5484):1560-3. doi: 10.1126/science.289.5484.1560.'}, {'pmid': '17499603', 'type': 'BACKGROUND', 'citation': 'Deshpande G, Rao S, Patole S. Probiotics for prevention of necrotising enterocolitis in preterm neonates with very low birthweight: a systematic review of randomised controlled trials. Lancet. 2007 May 12;369(9573):1614-20. doi: 10.1016/S0140-6736(07)60748-X.'}]}, 'descriptionModule': {'briefSummary': 'This prospective randomized double-blind control trial is carrying out in the neonatal unit of Sylhet MAG Osmani Medical College Hospital, Sylhet between July 2012 to December 2015 with the diagnosis of preterm (\\<33 weeks gestation) VLBW (birth weight \\<1500g) and fulfilling the inclusion criteria (able to tolerate oral feed and survive beyond 48h of life) were included in this study. Babies with suspicion of clinical sepsis, presence of perinatal asphyxia, major congenital anomaly and babies who expired due to other neonatal illness were excluded. Gestation was assessed from history of last menstrual period and after birth by new Ballard scores. A study protocol was approved by the Institutional Ethics Committee of Sylhet M.A.G Osmani Medical College, Sylhet.', 'detailedDescription': "Background: Necrotizing enterocolitis (NEC) is the most common acquired disease of the gastrointestinal tract in preterm very low birth weight infants and associated with increased morbidity and mortality. Prophylactic enteral probiotic supplementation may play a role in reducing NEC and potentially provide benefits to preterm very low birth weight neonates. The objective was to evaluate the efficacy of orally administered probiotics in preventing necrotizing enterocolitis (NEC) in preterm very low birth weight (VLBW) infants.\n\nThis prospective, randomized double blind controlled trial is undergoing in 102 preterm (28-33 weeks gestation) VLBW (birth weight 1000-1499g) neonates fulfilling the inclusion criteria. The study group was fed with probiotics once daily with breast milk from first feeding and the control group only breast milk without the addition of probiotics. The primary outcome was the development of NEC (stage II and III). NEC is categorized by modified Bell's classification.\n\nProbiotic supplementation reduces the frequency of necrotising enterocolitis in preterm neonates with very low birth weight. It is also associated with faster achievement of full enteral feeding and shorter duration of hospital stay."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '33 Weeks', 'minimumAge': '1 Week', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* All newborn infant preterm (\\<33 weeks gestation to 28 weeks gestation) VLBW (birth weight \\<1500gm to 1000 gm)\n* Able to tolerate oral feed\n* Informed consent by the parents or guardian\n\nExclusion Criteria:\n\n* Evidence or suspicion of clinical sepsis before the baby is randomised\n* Presence of perinatal asphyxia\n* Presence of major congenital anomali\n* Death within first week of life due to other neonatal illness'}, 'identificationModule': {'nctId': 'NCT02650869', 'acronym': 'Probiotics', 'briefTitle': 'Role of Probiotics for Prevention of NEC in Preterm VLBW Infants', 'organization': {'class': 'OTHER', 'fullName': 'Sylhet M.A.G.Osmani Medical College'}, 'officialTitle': 'Role of Probiotics for Prevention of Necrotizing Enterocolitis in Preterm Very Low Birth Weight Infants: A Double Blind Randomized Controlled Trial', 'orgStudyIdInfo': {'id': 'SylhetMAG'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Standard care + Breast milk+ Probiotics', 'description': 'The study group will be fed with probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU) dissolved with 6 ml of milk then give 3 ml (3 billion probiotics) once daily with breast milk from first feeding.', 'interventionNames': ['Dietary Supplement: Probiotics']}, {'type': 'ACTIVE_COMPARATOR', 'label': 'Standard care', 'description': 'The control group will be given standard care without the addition of probiotics', 'interventionNames': ['Dietary Supplement: Breast milk']}], 'interventions': [{'name': 'Probiotics', 'type': 'DIETARY_SUPPLEMENT', 'otherNames': ['TS 6 Probiotics'], 'description': 'probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)', 'armGroupLabels': ['Standard care + Breast milk+ Probiotics']}, {'name': 'Breast milk', 'type': 'DIETARY_SUPPLEMENT', 'description': 'Normal breast milk will be given as part of standard care', 'armGroupLabels': ['Standard care']}]}, 'contactsLocationsModule': {'overallOfficials': [{'name': 'Prof. M. Monojjir Ali, FCPS', 'role': 'STUDY_CHAIR', 'affiliation': 'Professor and Head, Department of Paediatrics, Sylhet M.A.G.Osmani Medical College'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sylhet M.A.G.Osmani Medical College', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Consultant', 'investigatorFullName': 'Dr. Fazle Rabbi Chowdhury', 'investigatorAffiliation': 'Sylhet M.A.G.Osmani Medical College'}}}}